Just three months after Achillion started a Phase Ia study for
ACH-3102, which was used for a classic safety check, investigators
ramped up a Ib trial with 14 patients. Today it reported that the NS5A
inhibitor, billed as a next-gen competitor for the oral, interferon-free
combo treatments now in the clinic, produced a significant reduction in
viral load after a range of single doses were tested. A mean maximum
3.74 log reduction in HCV RNA was recorded for genotype 1a patients,
with resistant variants also responding.
With the 14-day efficacy results completed, Achillion has already
jumped into a 12-week Phase II study of 3102 combined with ribavirin for
genotype 1b. And investigators will test the sustained virologic
response level, with that data coming in the fourth quarter of this
year. Altogether, Phase Ia through an initial Phase II is being executed
in less than five months, a pace rarely matched in the slow-moving drug
development. Achillion also has its lead NS3 protease, ACH-1625
(sovaprevir), in mid-stage studies.